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BACKGROUND: Since the 1970s there have been few epidemiological studies of scrotal cancer. We report on the descriptive
epidemiology of scrotal cancer in the Netherlands.
METHODS: Data on all scrotal cancer patients were obtained from the Netherlands Cancer Registry (NCR) in the period 1989–2006
and age-standardised incidence rates were calculated also according to histology and stage. Relative survival was calculated and
multiple primary tumours were studied.
RESULTS: The overall incidence rate varied around 1.5 per 1 000 000 person-years, most frequently being squamous cell carcinoma
(27%), basal cell carcinoma (19%) and Bowen’s disease (15%). Overall 5-year relative survival was 82%, being 77% and 95%
for patients with squamous and basal cell carcinoma, respectively. In all, 18% of the patients were diagnosed with a second
primary tumour.
CONCLUSION: The incidence rate of scrotal cancer did not decrease, although this was expected; affected patients might benefit from
regular checkups for possible new cancers.
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Pott (1775) described a relationship between soot exposure and a
high incidence of scrotal cancer among chimney sweepers. Scrotal
cancer has also been linked to exposure to tar (Henry, 1947;
Waldron et al, 1984; Sorahan et al, 1989), pitch (Waldron et al,
1984; Sorahan et al, 1989), different types of lubricating and
cutting oils (Kickham and Dufresne, 1967; Lee et al, 1972;
Wahlberg, 1974; Lee, 1976; Roush et al, 1984; Waldron et al,
1984; Sorahan et al, 1989; Parys and Hutton, 1991; Coggon et al,
1996), creosotes (Heller, 1930; Henry, 1947), gas production
(Henry, 1947; Doll et al, 1972), paraffin wax pressing (Lione and
Denholm, 1959) and various treatments for skin diseases (Andrews
et al, 1991; Stern and Laird, 1994; Stern et al, 2002). With the
knowledge on occupational risk factors and the accompanying
improvements in working conditions, scrotal has become rare. In
the 1970s and early 1980s, its incidence in the United States was
about one per million person-years, but has been increasing again
since then (Roush et al, 1984; Weinstein et al, 1989; Goldoft and
Weiss, 1992; Wright et al, 2008).
Scrotal cancer should not be confused with the more common
testicular cancer, that mainly affects young adults. The scrotum is the
protuberance of muscles and skin containing the testicles. Therefore
most scrotal tumours are sarcomas or skin tumours whereas
testicular cancers are usually germ-cell tumours. Tumours of the
skin of the scrotum might also be classified as skin cancer, but owing
to the historically strong aetiological relationship between scrotal
tumours and occupational exposures and the lack of this relationship
between occupational exposures and other tumours of the skin,
scrotal tumours are classified as a separate entity.
Little information on the incidence and survival of scrotal
cancer has been published in the last 20 years, probably because it
was expected that the incidence would become almost zero after
removal of the known scrotal carcinogens from the working
environment. Given the relative lack of recent work, we have used
recent Dutch data to investigate the stage distribution, histological
distribution, incidence, survival and occurrence of second primary
tumours in patients with this rare cancer since 1989.
MATERIALS AND METHODS
Data were used from the nation-wide population-based Nether-
lands Cancer Registry (NCR), which combines the data from the
eight Dutch regional cancer registries since 1989. These registries
receive lists of newly diagnosed cancer patients on a regular basis
from hospital pathology departments, all participating in a nation-
wide network (PALGA). In addition, hospital medical records
departments provide lists of diagnoses of outpatients and
hospitalised cancer patients. Following these notifications, trained
registrars extract patient and tumour characteristics (among other
things, topography, histology, stage and date of diagnosis) data
from the medical records. According to the registration rules of the
NCR, scrotal skin tumours are categorised in the topographic
group of scrotal cancer and not in the group of skin cancers.
Topography and histology were coded according to the
International Classification of Diseases for Oncology (ICD-O;
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Fritz et al, 2000). All tumours with an ICD-O topography code
scrotum (C63.2) were selected for this study. We grouped the
histological codes according to the classification in Table 1. For all
other analyses, lymphomas and mesotheliomas of the scrotum
were excluded.
The stage of the squamous cell carcinomas, basal cell
carcinomas, Paget’s diseases and the tumours that were grouped
in the histological ‘other’ group was categorised according to the
IUCC carcinoma of the skin TNM classification (Sobin and
Wittekind, 2002): stage 0 (TisN0M0), stage 1 (T1N0M0), stage 2
(T2–3N0M0), stage 3 (T4N0M0, any T N1M0) and stage 4
(any T, any N, M1). The stage of the melanomas diagnosed before
2003 was categorised according to the fifth TNM classification of
malignant melanomas of the skin, and since 2003 and later,
according to the sixth TNM classification (Sobin and Wittekind,
1997, 2002). Because Bowen’s disease tumours are by definition
in situ tumours and because sarcomas have no current TNM-
classification these groups were excluded from the analyses
according to stage.
Age and stage distributions were calculated according to histology.
Five-year moving-average age-standardised incidence rates were
calculated per 1 000 000 person-years for the entire group of scrotal
cancers. Age-standardised incidence rates in 6-year diagnostic
periods per 1 000 000 person-years were calculated according to
histology. Standardisation of age was performed according to the
European standard population. The Joinpoint regression program
(v3.0, Statistical Research and Applications Branch, National Cancer
Institute, Information Management Services, Inc., Silver Spring, MD,
USA, http://www.srab.cancer.gov/joinpoint) was used to test whether
there were increases or decreases in the overall incidence rate of
scrotal cancer (Kim et al, 2000).
The frequency of patients with invasive primary tumours before
and/or after scrotal cancer diagnosis was calculated. The strict
rules of the NCR on registering second primary tumours ensured
that only primary tumours were included in this analysis, as
tumours with the same ICD-O topography group had to be
diagnosed with a time difference of at least 6 months or had to
belong to different morphological groups. For squamous cell
carcinomas of the skin, only the first tumour could be included in
the analyses owing to differences in registration methods over time
and between regions.
Vital status data (available until 1 January 2008) were obtained
from the hospital records and the mortality register of the Central
Bureau for Genealogy (an institution that registers all deaths in the
Netherlands via the municipal population registries). For patients
with two scrotal tumours, only data on the first tumour were used
for survival analyses. Relative survival was calculated for the total
group and also according to histology. Relative survival is an
estimation of the disease-specific survival, being the absolute
survival among the scrotal cancer patients divided by the expected
survival for the general population with the same sex and age
structure (Hakulinen and Abeywickrama, 1985). Relative survival
was computed by means of traditional cohort analysis.
RESULTS
In all, 200 scrotal tumours in 194 patients were diagnosed in
1989–2006 in the Netherlands; their histology is shown in Table 1.
The largest histological groups were squamous cell carcinomas
(27%), basal cell carcinomas (19%), Bowen’s disease (15%),
sarcomas (13%) and extramammary Paget’s disease (12%).
Mesotheliomas and lymphomas were excluded from further
analyses. Patients with basal cell carcinomas were oldest at
diagnosis with a median age of 72 years, whereas patients with
scrotal sarcoma had a median age of 56.5 years (Figure 1).
In the study period, the age-standardised 5-year moving-average
incidence rate varied between 0.9 and 1.8 per 1 000 000 male
person-years (Figure 2), with no statistically significant increase or
decrease over time.
Figure 3 presents age-standardised scrotal cancer incidence
rates in 6-year periods according to histology. The highest
incidence rates were found for squamous cell and basal cell
carcinomas and the lowest incidence rates for the malignant
melanomas and ‘other’ group. During 1995–2000, the incidence
rates of scrotal squamous cell carcinoma, basal cell carcinoma,
Paget’s disease, sarcoma and the ‘other’ group seem to have
increased temporarily. The stage distribution of the different
histological groups is presented in Table 2. In all histological
groups there are large percentages of tumours with an unknown
stage, ranging from 13 to 47%. The majority of the patients with
squamous cell carcinoma, basal cell carcinoma and Paget’s disease
had stage 1 or 2 tumours, whereas the majority of the malignant
melanomas were stage 2 or 3.
Data on vital patients were missing for 34 (18%) of the 189
patients, most of them were diagnosed before 1995 (n¼ 25). For
this period follow-up of vital status is still incomplete in most of
the regional cancer registries. Relative survival 1 year after
diagnosis was 97% (95% confidence interval (95% CI):
91–100%), which decreased gradually to 82% (95% CI: 71–90%)
5-year relative survival and overall crude survival being 66% (95%
CI: 58–74%). From 6 to 10 years after diagnosis, the relative
survival remained about 80%, resulting in a 10-year relative
survival of 77% (95% CI: 62–91%). Five-year survival estimates of
patients with scrotal basal cell carcinomas, Bowen’s diseases and
sarcomas were 95% or higher, yet with wide CIs. The 5-year
relative survival of patients with extramammary Paget’s disease
was 68% (95% CI: 36–94%), but 1- and 3-year relative survival
estimates were both 100%. The 1-, 3- and 5-year relative survival of
patients with squamous cell carcinomas was relatively low, being,
Table 1 Histological classification and distribution of scrotal cancer patients in the Netherlands
Histological group
Morphology code according to ICD-O
(Fritz et al, 2000) No. %
Squamous cell carcinoma and variants 8033, 8070, 8071, 8072, 8076, 8083, 8094 53 27
Basal cell carcinoma 8090, 8091, 8096 38 19
Bowen’s disease 8081 29 15
Sarcoma 8804, 8810, 8850, 8851, 8852, 8853, 8857, 8890, 8900 26 13
Extramammary Paget’s disease 8542 24 12
Malignant melanoma 8720, 8721, 8743 16 8
Lymphoma 9675, 9680, 9699 4 2
Mesothelioma 9050 1 1
Other 8000, 8010, 8051, 8140, 8247, 8400, 8402, 8410, 8830 9 5
Total 200 100
Abbreviation: ICD-O¼ International Classification of Diseases for Oncology.
The epidemiology of scrotal cancer in the Netherlands
RHA Verhoeven et al
1463
British Journal of Cancer (2010) 103(9), 1462 – 1466& 2010 Cancer Research UK
E
p
id
e
m
io
lo
g
y
respectively, 93% (95% CI: 79–100%), 80% (95% CI: 61–94%) and
77% (95% CI: 56–94%).
The distributions of the tumours diagnosed before or after the
first diagnosis of scrotal cancer are presented in Table 3. A high
percentage of skin tumours and tumours located near the scrotum
(penis, prostate, anal canal, urinary bladder, colorectal, etc.) was
found both before and after the diagnosis of scrotal cancer. Six
men with a scrotal cancer (three with Bowen’s disease, one with
squamous cell carcinoma, one with basal cell carcinoma and one
with some ‘other’ tumour) were diagnosed with a second scrotal
tumour, three of these second scrotal tumours were squamous cell
carcinomas, two belonged to the other category and one was a
Bowen’s disease. Four of these six patients also had other tumours
(i.e. two cutaneous, one tumour of soft tissue, lung, larynx tumour
or bladder, and one plasma cell tumour).
The 24 tumours detected before the diagnosis of scrotal cancer
were found in 22 patients (12%) and 34 patients (18%) had at least
one cancer diagnosis after the first scrotal cancer diagnosis in
1989–2006.
DISCUSSION
During 1989–2006, scrotal cancer occurred predominantly in men
older than 50 years. The age-standardised incidence rate was
around 1.5 per 1 000 000 person-years and did not seem to change
over time. Squamous cell carcinomas were the most frequent
histological type, followed by basal cell carcinomas. The stage of
most tumours was unknown or low. The relative survival of scrotal
patients was good. Multiple primary tumours were quite common
among patients with scrotal cancer.
The incidence of scrotal cancer in the United Kingdom
decreased during the 1970s and the early 1980s, probably because
of previous improvement in the occupational hygiene and the
removal of carcinogens; a further decrease in incidence was
expected (Sorahan et al, 1989). However, although we found a
relatively steady incidence, a recent American study found an
increase since the early 1980s (Wright et al, 2008). This may
indicate that not only occupational exposures influence the risk of
scrotal cancer, which is also indicated by the histological
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Figure 1 Age distribution of patients diagnosed with scrotal cancer in the Netherlands according to histology (median, Q1, Q3, lowest and highest age).
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Figure 2 Five-year moving-average European standardised scrotal cancer incidence rates per 1 000 000 person-years (mesotheliomas and lymphomas
excluded).
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distribution. In this study, 27% of the tumours were squamous cell
carcinomas and 15% Bowen’s disease (in situ squamous cell
carcinomas), whereas previous studies reported that the great
majority were squamous cell carcinomas (up to 93%; Kickham and
Dufresne, 1967; Ray and Whitmore, 1977; McDonald, 1982; Parys
and Hutton, 1991). The recent US study reported a similar
percentage of squamous cell carcinomas (32%) as our study
(Wright et al, 2008). Because almost all occupationally caused
scrotal tumours were squamous cell carcinomas (Kickham and
Dufresne, 1967), the current low proportion of such tumours may
indicate that certain non-occupational exposures are relevant.
Possible non-occupational risk factors are sun exposure, several
types of treatments for skin diseases and the human papilloma
virus (Andrews et al, 1991; Stern and Laird, 1994; Guran and Pak,
1999; Stern et al, 2002; de Vries et al, 2006).
The relatively high percentage of tumours with unknown stage
in this study probably reflects the very good prognosis of most
tumours. In general, these superficial tumours are surgically
removed without further staging or treatment. If most tumours
with unknown stage tumours are indeed of lower stage, the
percentage of lower stage (stage 0, 1 or 2) would be around 90%,
being somewhat higher than that in other studies (McDonald,
1982; Roush et al, 1985; Wright et al, 2008).
Both our study and the recently published study in the United
States found that survival of patients with squamous cell
carcinomas of the scrotum seems to be lower than that of patients
with a scrotal basal cell carcinoma or sarcoma (Wright et al, 2008).
Some extra therapeutic caution may thus be needed for scrotal
squamous cell carcinomas. The 5-year relative survival of scrotal
squamous cell carcinoma patients (77%) was also lower, although
not significantly, than the 5-year relative survival of male skin
squamous cell carcinoma patients in the Netherlands (91%)
(http://www.ikcnet.nl/page.php?id¼ 224). Previous studies have
not calculated relative survival based on reasonable numbers of
scrotal cancer patients. A study in a region of the United Kingdom
including 324 patients diagnosed in 1936–1976 reported crude
5-year survival estimates of 51%, with no change over time
(Waldron et al, 1984), which, albeit being significantly lower than
our crude 5-year survival of 66%, is not largely different.
Of scrotal cancer patients, 18% developed one or more tumours
after the scrotal tumour and six (3%) patients developed a second
scrotal cancer. All of these tumours were diagnosed in the period
1989–2006, so patients who were diagnosed recently only had a
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Figure 3 European standardised scrotal cancer incidence rates per 1 000 000 person-years according to histology.
Table 2 Number of scrotal tumours according to stage and histology
Stage
Squamous cell
carcinoma
Basal cell
carcinoma
Paget’s
disease
Malignant
melanoma Other
0 1 0 2 0 1
1 22 12 2 1 2
2 18 8 9 6 1
3 2 0 2 6 1
4 0 0 0 1 1
Unknown 10 18 9 2 3
Total 53 38 24 16 9
The histological groups ‘sarcomas’, ‘lymphomas’ and ‘mesotheliomas’ do not have a
TNM stage distribution and the ‘Bowen’s disease’ are by definition in situ tumours;
therefore these histologies are not included in this table.
Table 3 Tumours of scrotal cancer patients diagnosed before and after
the first diagnosis of scrotal cancer
Site
Number of tumours
before scrotal cancer
Number of tumours
after scrotal cancer
Skin, squamous cell
carcinoma
9 7
Lung 1 8
Colorectal 5 4
Scrotum NA 6
Prostate 2 4
Non-Hodgkin’s
lymphoma
2 1
Urinary bladder 2 1
Anal canal 1 1
Skin, melanoma 1 1
Chronic
myeloproliferative
disorder
1 0
Eye 0 1
Larynx 0 1
Pancreas 0 1
Penis 0 1
Plasma cell tumour 0 1
Primary site unknown 0 1
Skin, other 0 1
Soft tissue 0 1
Total 24 41
Abbreviation: NA¼ not applicable.
The epidemiology of scrotal cancer in the Netherlands
RHA Verhoeven et al
1465
British Journal of Cancer (2010) 103(9), 1462 – 1466& 2010 Cancer Research UK
E
p
id
e
m
io
lo
g
y
short time to manifest a second (scrotal) tumour, and a longer
follow-up would probably reveal a higher percentage of second
(scrotal) cancers. This also applies to tumours that were diagnosed
before the scrotal cancer diagnosis. However, the number of
scrotal tumours and the number of tumours diagnosed after a
first scrotal tumour could also have been increased by increased
surveillance on new tumours by medical specialists in the patients
who were already diagnosed with a previous tumour. Regular
follow-up of scrotum cancer patients might thus be useful to detect
new tumours at an early stage, but might also result in
overdiagnosis.
In another study, 8 of the 19 patients with a squamous cell
carcinoma of the scrotum had a cancer in their medical history, 5
of these 8 previous cancers were skin cancers (Weinstein et al,
1989). A patient series from the UK reported 69 (20%) of the 344
scrotal cancer patients to have second primary tumours, similar to
our study (Waldron et al, 1984). It is generally known that people
with skin tumours have a high chance of developing more skin
cancers; scrotal skin cancer does not seem to be an exception
(Marcil and Stern, 2000).
We found the incidence of scrotal cancer to be relatively stable,
varying between 0.9 and 1.8 per million person-years, although we
had expected a decreasing trend. The largest histological groups
were the squamous cell carcinomas, basal cell carcinomas and
Bowen’s disease. The 5-year relative survival for the whole group
of scrotal cancer patients was high (81%). The high percentage
of second primary tumours after scrotal cancers suggests that
scrotal cancer patients might benefit from regular checkups for
possible new cancers.
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